These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24796503)

  • 1. Improvement of pulmonary surfactant activity by introducing D-amino acids into highly hydrophobic amphiphilic α-peptide Hel 13-5.
    Nakamura Y; Yukitake K; Nakahara H; Lee S; Shibata O; Lee S
    Biochim Biophys Acta; 2014 Aug; 1838(8):2046-52. PubMed ID: 24796503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of low cost pulmonary surfactants composed of a mixture of lipids or lipids-peptides using higher aliphatic alcohol or soy lecithin.
    Yukitake K; Nakamura Y; Kawahara M; Nakahara H; Shibata O; Lee S
    Colloids Surf B Biointerfaces; 2008 Oct; 66(2):281-6. PubMed ID: 18762408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Langmuir monolayer of artificial pulmonary surfactant mixtures with an amphiphilic peptide at the air/water interface: comparison of new preparations with surfacten (Surfactant TA).
    Nakahara H; Lee S; Sugihara G; Chang CH; Shibata O
    Langmuir; 2008 Apr; 24(7):3370-9. PubMed ID: 18315015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode of interaction of hydrophobic amphiphilic alpha-helical peptide/dipalmitoylphosphatidylcholine with phosphatidylglycerol or palmitic acid at the air-water interface.
    Nakahara H; Lee S; Sugihara G; Shibata O
    Langmuir; 2006 Jun; 22(13):5792-803. PubMed ID: 16768510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hysteresis behavior of amphiphilic model peptide in lung lipid monolayers at the air-water interface by an IRRAS measurement.
    Nakahara H; Dudek A; Nakamura Y; Lee S; Chang CH; Shibata O
    Colloids Surf B Biointerfaces; 2009 Jan; 68(1):61-7. PubMed ID: 18977123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An amphipathic alpha-helical decapeptide in phosphatidylcholine is an effective synthetic lung surfactant.
    McLean LR; Lewis JE; Krstenansky JL; Hagaman KA; Cope AS; Olsen KF; Matthews ER; Uhrhammer DC; Owen TJ; Payne MH
    Am Rev Respir Dis; 1993 Feb; 147(2):462-5. PubMed ID: 8430972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixtures of synthetic peptides and dipalmitoylphosphatidylcholine as lung surfactants.
    McLean LR; Krstenansky JL; Jackson RL; Hagaman KA; Olsen KA; Lewis JE
    Am J Physiol; 1992 Mar; 262(3 Pt 1):L292-300. PubMed ID: 1550252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome.
    Cochrane CG; Revak SD; Merritt TA; Heldt GP; Hallman M; Cunningham MD; Easa D; Pramanik A; Edwards DK; Alberts MS
    Am J Respir Crit Care Med; 1996 Jan; 153(1):404-10. PubMed ID: 8542150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of amphiphilic alpha-helical model peptides with systematically varied hydrophobic-hydrophilic balance and their interaction with lipid- and bio-membranes.
    Kiyota T; Lee S; Sugihara G
    Biochemistry; 1996 Oct; 35(40):13196-204. PubMed ID: 8855958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial pulmonary surfactant as a carrier for intratracheally instilled insulin.
    Ji Y; Liu C; Pei YY
    Acta Pharmacol Sin; 2007 May; 28(5):744-50. PubMed ID: 17439732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical properties and surface activity of surfactant-like membranes containing the cationic and hydrophobic peptide KL4.
    Sáenz A; Cañadas O; Bagatolli LA; Johnson ME; Casals C
    FEBS J; 2006 Jun; 273(11):2515-27. PubMed ID: 16704424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotubules formed by highly hydrophobic amphiphilic alpha-helical peptides and natural phospholipids.
    Furuya T; Kiyota T; Lee S; Inoue T; Sugihara G; Logvinova A; Goldsmith P; Ellerby HM
    Biophys J; 2003 Mar; 84(3):1950-9. PubMed ID: 12609897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases.
    Mazela J; Merritt TA; Gadzinowski J; Sinha S
    Acta Paediatr; 2006 Sep; 95(9):1036-48. PubMed ID: 16938747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the hydrophobic face of amphipathic alpha-helical peptides in synthetic pulmonary surfactants.
    McLean LR; Lewis JE; Hagaman KA; Owen TJ; Matthews ER
    J Pharmacol Exp Ther; 1993 Aug; 266(2):551-6. PubMed ID: 8355190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic mimics of surfactant proteins B and C: in vitro surface activity and effects on lung compliance in two animal models of surfactant deficiency.
    Bruni R; Hernández-Juviel JM; Tanoviceanu R; Walther FJ
    Mol Genet Metab; 1998 Feb; 63(2):116-25. PubMed ID: 9562965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KL4-surfactant prevents hyperoxic and LPS-induced lung injury in mice.
    Kinniry P; Pick J; Stephens S; Jain D; Solomides CC; Niven R; Segal R; Christofidou-Solomidou M
    Pediatr Pulmonol; 2006 Oct; 41(10):916-28. PubMed ID: 16871629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific interaction restrains structural transitions of an amphiphilic peptide in pulmonary surfactant model systems: an in situ PM-IRRAS investigation.
    Nakahara H; Lee S; Shibata O
    Biochim Biophys Acta; 2010 Jun; 1798(6):1263-71. PubMed ID: 20175990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biophysical activity of an artificial surfactant containing an analogue of surfactant protein (SP)-C and native SP-B.
    Palmblad M; Johansson J; Robertson B; Curstedt T
    Biochem J; 1999 Apr; 339 ( Pt 2)(Pt 2):381-6. PubMed ID: 10191270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interfacial behavior of pulmonary surfactant preparations containing egg yolk lecithin.
    Nakahara H; Shibata O
    J Oleo Sci; 2014; 63(11):1159-68. PubMed ID: 25296574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
    Fujii A; Allen R; Doros G; O'Brien S
    J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.